|
BRPI0416141A
|
|
Modified anti-cd52 antibody, pharmaceutical composition, expression vectors, and method for preparing an immunoglobulin
|
|
GB0406837D0
|
|
Recombineering based expression
|
|
GB0406836D0
|
|
Expression cell lines employing RNA trans-splicing
|
|
GB0405927D0
|
|
Cell fusion driven protein expression
|
|
AU2004201047A1
|
|
Protein isolation and analysis
|
|
GB0304767D0
|
|
Device and methods for foetal cell analysis
|
|
GB0018901D0
|
|
Peptides presented by cells
|
|
GB0015954D0
|
|
Device and methods for foetal cell analysis
|
|
GB0011125D0
|
|
Combined rapid diagnosis and therapy
|
|
GB0011126D0
|
|
High order nucleic acid-based structures
|
|
GB0008466D0
|
|
Cell fusion driven protein expression
|
|
BR0009206A
|
|
Protein isolation and analysis
|
|
US6927025B1
|
|
Methods for protein screening
|
|
WO0034317A2
|
|
Method for reducing immunogenicity of proteins
|
|
GB9926810D0
|
|
High order nucleic acid-based structures
|
|
GB9926812D0
|
|
Modified immunoglobulin E molecules
|
|
GB9926809D0
|
|
Bispecific molecules to inhibit immuno-receptor activation
|
|
GB9926811D0
|
|
Combined rapid diagnosis and therapy
|
|
GB9922285D0
|
|
Protein analysis
|
|
GB9920503D0
|
|
Protein analysis
|
